Firms Have Advanced Space-Based Drug Manufacturing
Biotech companies are developing orbital platforms for medicine as regulators prepare new approval frameworks.
Updated on Sept. 19, 2026 in Biotech
Live Poll
Should private companies prioritize manufacturing medical treatments in space to advance research?
Pharmaceutical firms are building dedicated orbital platforms for manufacturing medicines in low Earth orbit, leveraging microgravity to improve biological material production. As current International Space Station research continues, regulators are now drafting guidelines to approve treatments created in space.
Why it matters
Microgravity enables the precise distribution of cells and particles in biological materials that is difficult to achieve on Earth, potentially improving drug efficacy. With the International Space Station slated for retirement, private orbital platforms are essential to scale this production.
LambdaVision has completed nine missions to the International Space Station since 2018 to research manufacturing. New commercial platforms like Starlab are now being designed with automation and dedicated lab areas to replace limited station capacity.
The players
LambdaVision
This company focuses on developing protein-based artificial retina technology using microgravity manufacturing.
NASA
This U.S. government agency manages the civil space program and provides the primary existing platform for orbital research.
Medicines and Healthcare Products Regulatory Agency
This British government agency is responsible for ensuring that medicines and medical devices work and are acceptably safe.
Merck
This multinational pharmaceutical corporation investigates advanced manufacturing processes for its drug portfolio.
The details
Companies including Auxilium Biotechnologies and Merck have utilized the International Space Station for experiments ranging from 3D bioprinting of human tissues to refining drug formulations. Future platforms developed by firms such as Axiom Space and Varda Space Industries aim to provide rental laboratory space to sustain these efforts beyond the station's lifespan.
Timeline
LambdaVision began its mission series in 2018.
British regulators announced development of guidance in March 2026.
A roadmap for space medicine regulation is expected by the end of 2026.
NASA plans to retire the International Space Station by the end of the decade.
LambdaVision aims to initiate clinical trials in 2028.
The Tech Race
This move signals a shift from short-term orbital testing to sustained commercial manufacturing in space. It follows the precedent set by the 2018 memorandum of understanding between the US Food and Drug Administration and NASA to bridge the gap between orbital research and terrestrial drug approval.
Successful orbital manufacturing could lead to more effective medications for various diseases by improving the structural quality of biological compounds. Consumers may eventually see new, high-potency drugs arrive on the market as clinical trials proceed later this decade.
The takeaway
The transition to commercial orbital platforms marks the maturation of space as a viable manufacturing sector for the pharmaceutical industry. Readers should monitor upcoming regulatory roadmaps as these frameworks will dictate when space-made therapies become available for human use.
Further reading
Learn more about the latest innovations in the field on our Biotech section page.
Source note: This article includes information reported by Taipei Times.
Live Poll
Should private companies prioritize manufacturing medical treatments in space to advance research?
